COMPREHENSIVE EVALUATION OF CHRONIC KIDNEY DISEASE PROGRESSION IN PATIENTS WITH METABOLIC DISORDERS.

 

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

 


 

Certificate Background

   

Presented the abstract " "
(Abstract co-author(s):  )

 

 

E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center. 

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

​E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.​

E-Poster Format Requirements
  • PDF file
  • Layout: Portrait (vertical orientation)
  • One page only (Dim A4: 210 x 297mm or PPT)
  • E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
  • File Size: Maximum file size is 2 Megabytes (2 MB)
  • No hyperlinks, animated images, animations, and slide transitions
  • Language: English
  • Include your abstract number
  • E-posters can include QR codes, tables and photos
 
COMPREHENSIVE EVALUATION OF CHRONIC KIDNEY DISEASE PROGRESSION IN PATIENTS WITH METABOLIC DISORDERS.

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

  • The title will not be accepted if it exceeds 25 words.
  • Type in CAPITAL LETTERS.
  • Lowercase may be used for abbreviations only, for example, mRNA.
Guzal
Karimdjanova
Guzal Karimdjanova karimdjanovaguzal@gmail.com Tashkent state medical university Internal medicine, Nephrology ang hemodialysis Tashkent Uzbekistan *
Dano Egamberdieva egamberdievadano@gmail.com Tashkent state medical university Internal medicine, Nephrology ang hemodialysis Tashkent Uzbekistan -
-
-
-
-
-
-
-
-
-
-
-
-
-

Chronic kidney disease (CKD) represents a growing global health problem associated with high cardiovascular morbidity and mortality. Metabolic syndrome (MS), characterized by a cluster of interrelated risk factors such as abdominal obesity, dyslipidemia, hypertension, and impaired glucose metabolism, plays a key role in the development and progression of CKD. The combined presence of these metabolic abnormalities accelerates renal dysfunction through mechanisms involving endothelial damage, inflammation, and oxidative stress. Despite this, the relationship between MS and CKD progression remains insufficiently studied in hospitalized cardiology patients.

The aim of this study was to study the relationship between the metabolic syndrome and the risk of CKD progression in a representative sample of patients who were hospitalized at the Department of Cardiology and Interventional Cardiology of the Republican Specialized Scientific and Practical Medical Center for Therapy and Medical Rehabilitation.

In the prospective part of the study, information on demographic characteristics, including age, gender, education, and occupation, was collected from doctor's visits using a standard questionnaire. Metabolic syndrome was defined according to international guidelines in the presence of three or more of the following risk factors: waist circumference >102 cm in men or >88 cm in women; serum triglyceride level ≥1.70 mmol/l; HDL cholesterol level <1.04 mmol/l in men or <1.30 mmol/l in women; BP ≥ 130/85 mm Hg, including achieved; serum glucose level ≥6.11 mmol/l. The criteria for determining the metabolic syndrome were used.

Demographic characteristics of patients are presented in the table. Mean serum creatinine was similar, but GFR was estimated to be lower among those with metabolic syndrome compared to those without. The percentage of individuals with CKD and elevated serum creatinine was statistically significantly higher among those with metabolic syndrome. It turned out that low HDL cholesterol, elevated plasma glucose and abdominal obesity were statistically significantly associated with the risk of developing C5 CKD and elevated serum creatinine. In addition, there was a significant relationship between the number of metabolic syndrome components and the percentage of C5 CKD or elevated serum creatinine (P<0.015 and P=0.02, respectively). In the multivariate model, patients with 1, 2, 3, and 4 or 5 components of the metabolic syndrome had 1.51; 1.50; 2.13- and 2.72-times higher chances of CKD C5 CKD, respectively, compared to individuals without metabolic syndrome components. Overall, patients with metabolic syndrome had a 64% increase in the odds of CKD compared to the comparison group without metabolic syndrome.

In the present study, a positive and significant relationship was found between the metabolic syndrome and the risk of C5 CKD in the examined patients. The risk of CKD increased progressively with an increase in the number of components of the metabolic syndrome. 

Kewords